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Abstract: The present study aimed to determine P-glycoprotein expression according to TVT cell morphology in 42
dogs with confirmed TVT, classified into lymphocytoid, plasmocytoid, and mixed. The chemotherapy efficiency was
investigated along with its relation to P-glycoprotein expression in tumoral cells, evaluated by immunocytochemistry,
considering positive tumors more than 10% stained. Among the samples collected, 50.00% possessed plasmocytoid
morphology, 18.63% lymphocytoid, and 31.37% mixed. The plasmocytoid presented greater immunoreactivity to the
anti-P-glycoprotein antibody in relation to the lymphocytoid. It was observed that the plasmocytoid was less sensitive to
chemotherapy. The cases that had partial clinical response in the lymphocytoid were less compared with those in the
plasmocytoid. Therefore, we can infer that the plasmocytoid presents a potential drug resistance. Based on this study, it
can be concluded that the plasmocytoid presents a higher frequency of partial clinical response than the lymphocytoid
and mixed, possibly through its higher percentage of anti-P-glycoprotein antibody expression.
Key words: Dog, TVT, P-glycoprotein, cell morphology

Introduction
Spontaneous canine transmissible venereal tumor
(TVT) is a neoplasia of round cells that can be
transmitted by transplant of viable tumor cells from one
animal to another during copulation or through licking,
biting, or scratching, especially in the presence of

abrasions or loss of surface integrity. Although
extragenital localization is also possible, it occurs most
frequently in the mucous membrane of the external
genitalia of stray, sexually active medium-sized dogs, of
both sexes, and presents global distribution, though is
most common in tropical and subtropical regions (1-3).
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The TVT metastases may reach virtually all organs
including the superficial and deep lymph nodes in the
subcutaneous abdominal and thoracic cavities, liver,
spleen, kidneys, lungs, and mediastinum (3-6).
Cytology is the method of choice for diagnosis
since it is rapid, simple, and presents little invasiveness
(7,8). Cytological samples of TVT are generally
described as multicellular with round or oval cells
whose cytoplasmic borders are well defined. The
nucleus, round or oval, is frequently eccentric and of
variable size with thick granular chromatin and 1 or 2
prominent nucleoli (9). However, considering the
absence or presence of cytoplasmic vacuoles, the
cellular size and form, and the nucleus-to-cytoplasm
ratio, TVT can be classified into 3 groups
denominated plasmocytoid, lymphocytoid, and
mixed (8,10).
Among the various treatment modalities such as
cryosurgery, radiotherapy, surgical resection, and
chemotherapy, the last of these is regarded as the most
effective and least invasive (11-15).
Although chemotherapy treatment may utilize
vincristine,
vimblastine,
doxorubicin,
and
cyclophosphamide as single agents or in combination,
administered in up to 8 cycles at weekly intervals (1618), resistance to drugs has been frequently observed
in TVT patients (10).
Resistance to chemotherapy is a multifactorial
phenomenon that can be conferred by various cellular
mechanisms related to defects in apoptosis regulation,
increase in intracellular detoxification, alterations in
DNA repair systems, and the activation or
overexpression of molecules such as P-glycoprotein.
P-glycoprotein constitutes part of a family of cell
transporters that function as an efflux pump
dependent on the energy generated by hydrolysis of
ATP, capable of translocating a series of drugs to the
cell exterior, thus reducing their intracellular
concentrations to levels of low lethality (19,21-23).
This protein is normally expressed in the adrenals,
kidneys, liver, colon, brain, lungs, peripheral blood,
and bone marrow (20,23). However, in both
veterinary and human oncology, it was demonstrated
that elevated P-glycoprotein expression levels
correlated positively with lack of response or
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remission of neoplasias after adequate forms of
chemotherapy (24,25). Nevertheless, there are data in
the literature that report the expression of Pglycoprotein among other cell groups different from
TVT.
The present study aimed to verify whether the
different cytomorphological groups of transmissible
venereal tumor (lymphocytoid, plasmocytoid, and
mixed) express P-glycoprotein at the same intensity,
enabling, in the future, adequate anticipatory
treatments given the observation of growing
resistance to chemotherapy in patients with this
neoplasia, especially in those with the plasmocytoid
pattern.
Materials and methods
Forty-two dogs of both sexes and of different
breeds were utilized, between the ages of 2 and 14
years, from the routine of the FMVZ, UNESP,
Veterinary Hospital, Botucatu, SP, Brazil, with
cytomorphological diagnosis of lymphocytoid,
plasmocytoid, or mixed TVT (8). For each animal, the
clinical genital and extragenital expression of the
lesion and the presence or absence of metastasis were
taken into consideration.
Samples of 102 neoplastic masses were collected
by punction or exfoliation. Half of each sample was
fixed and stained with Giemsa, and 100 neoplastic
cells were read and quantified per slide in a
mechanical counter, for inclusion in the experimental
groups: lymphocytoid, plasmocytoid, and mixed. The
other half of each sample was stored in Eppendorf
microtubes containing 1.5 mL of buffered saline
solution (PBS).
The samples suspended in PBS were divided into
aliquots of 50 μL and cytocentrifuged at 500 rpm for
3
min,
for
accomplishment
of
the
immunocytochemistry technique. Immunostaining
utilized the monoclonal antibodies anti-human antiP-glycoprotein clone 5B12 (Lab Vision, Fremont, CA,
USA) and anti-P-glycoprotein clone C494 (Signet
Laboratories, Dedham, MA, USA).
The slides were dehydrated by sequential passage
through alcohol. This was followed by the blocking of
endogenous peroxidase with 10 volumes of hydrogen
peroxide and then by washing with distilled running
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water. Afterwards, antigen recuperation was
performed in microwaves at maximum power while
maintaining the slides in citrate buffer, pH 6.0, for the
antibody anti-P-glycoprotein clone 5B12. For the
antibody anti-P-glycoprotein clone C494, the slides
were incubated with BSA 2%, for 1 h, at room
temperature.
Next, the slides were incubated with primary
antibody in a humid chamber at 4 °C for 18 h. Table
1 displays the antibody data like type of staining,
clone, brand, and standardized dilutions.
This was followed by incubation of the secondary
complex, utilizing the LSAB Kit (Dako Corporation,
Carpinteria, CA, USA) according to the
manufacturer’s instructions. For reaction revelation
the chromogen 3’-3’ diaminobenzidine was utilized
(Dako Carpinteria, CA, USA) for 5 min. Between all
steps the slides were washed with tris buffer.
The slides were counterstained with methyl green
for 5 min and washed with isopropyl alcohol for 2 min
(2 washings), and then passed though a battery of
dehydration and mounting.
The P-glycoprotein positive control utilized
histological cuts and an impression of a normal canine
liver while the negative control employed cytological
TVT samples incubated only with diluent of primary
antibody.
The slides were observed in an optical microscope,
at 40× magnification, and the results were expressed
as the percentage of positive cells among the 100 cells
per sample. Cells were considered positive if the
cytoplasmic membrane and cytoplasm were brown,
independent of the staining intensity, as described by
Ginn (22) and Miyoshi et al. (25).
To evaluate the efficacy of the response to
chemotherapy and its relation to expression of
membrane antigens, the 42 dogs received a
therapeutic protocol identical to vincristine sulfate
(0.75 mg/ m2, IV, q 7 d). The treatment duration

varied from 4 to 8 weeks. The response was
considered complete when tumor regression did not
surpass 4 weeks and partial when the regression was
from 5 to 8 weeks.
The relation of the clinical response by
cytomorphological group and P-glycoprotein
expression was investigated. Furthermore, the relation
of P-glycoprotein immunostaining to the clinical
response to chemotherapy was studied in 42
neoplastic masses.
The samples were compared according to
cytomorphological type and biological behavior and
analyzed at a 5% significance level by the chi-square
test with the Goodman test applied for comparison of
multinomial proportions.
Results
The tested antibody anti-P-glycoprotein clone
5B12 did not present positive staining in tissues that
physiologically express P-glycoprotein such as rigid
kidney and liver. Furthermore, antigen expression was
not demonstrated in TVT cells, even following the
recommendations of the literature and of the
manufacturer. After the attempts at antigen
recuperation by heating with EDTA and citrate and
the use of secondary systems and different
amplification without success, it was not incorporated
into the panel.
When the antibody anti-P-glycoprotein clone
C494 was utilized, positive staining was achieved at
1:100 dilution of primary antibody, both in positive
controls and in TVT cells. In the initial processing it
was not necessary to employ antigen recuperation by
heat, but for the diminution of non-specific stainings
and depth reduction, before incubation with primary
antibody, the cytological preparations were incubated
with BSA 2% for 1 h at room temperature. For the Pglycoprotein positive control histological cuts or the
impression of a normal canine liver was utilized and

Table 1. Primary antibody, staining type, brand, and standardized dilutions utilized.
Primary
antibody
Anti-P-glycoprotein

Type of
staining

Clone

Brand

Standardized
dilution

cytoplasmic

C494

Dako

1:100
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for the negative control, cytological TVT samples
incubated only with diluent of the primary antibody
were employed.
The replacement of streptavidine-biotin complex
by a secondary antibody system and polymer
associated with peroxidase, incubated at room
temperature for 1 h, resulted in a reduction of nonspecific stainings (background).
The cytoplasmic membrane staining of TVT cells
varied from discrete to intensely colored, generally
accompanied by diffuse cytoplasmic staining.
Of the 102 samples tested, 50.00% possessed
plasmocytoid morphology, 18.63% lymphocytoid,
and 31.37% mixed. Of the total, 46 (45%) presented
P-glycoprotein expression and 56 (55%) were
negative. The plasmocytoid group displayed a
significantly greater immunoreactivity to the anti-Pglycoprotein antibody (P < 0.05) than did the
lymphocytoid group (Table 2).
When the cytological preparations were regrouped
into primary and non-primary masses (Table 3), it

was observed that the non-primary group produced
superior immunoreactivity (67.65%), compared to the
primary group (32.35%) without a significant
difference.
The 42 clinical cases monitored were submitted to
the same therapeutic protocol (drug, administration
route, interval, and number of applications). In
analyzing the complete clinical response to
chemotherapy among the groups (Table 4), it was
observed that the plasmocytoid group was
significantly less sensitive to chemotherapy (P < 0.05)
in relation to lymphocytoid. Still, it was noted that the
percentage of cases that presented a partial clinical
response to chemotherapy in the lymphocytoid group
(36.37%) was lower than that in the plasmocytoid
group (80.95%).
By comparing the clinical response to chemotherapy
with the P-glycoprotein expression due to tumoral
resistance to some chemotherapies (Table 5), it was
observed that the group with partial response
presented a higher percentage of P-glycoprotein

Table 2. Number of cases (n) and percentage (%) of P-glycoprotein staining in samples
from different cytomorphological groups of transmissible venereal tumor.
Positive

Negative

GROUP

Lymphocytoid
Plasmocytoid
Mixed

Total
n

%

n

%

3a
b
29
ab
14

15.79
56.86
43.75

16
22
18

84.21
43.14
56.25

19
51
32

ab

Different letters represent significant differences for P < 0.05 (Goodman test for contrast
between multinomial proportions)

Table 3. Percentage of P-glycoprotein staining in samples of primary and non-primary
neoplasias in transmissible venereal tumor.
Primary

Non-primary

P-glycoprotein
n

%

n

%

Staining positive
Staining negative

26
43

37.68
62.32

19
14

57.57
42.43

Total

69

100

33

100

P = 0.11 by the chi-square test
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Table 4. Clinical response to chemotherapy among the different cytomorphological
groups of transmissible venereal tumor.
Complete response

Partial response

GROUP

Lymphocytoid
Plasmocytoid
Mixed

Total
n

%

n

%

7a
b
4
7a

63.63
19.05
70.00

4
17
3

36.37
80.95
30.00

11
21
10

ab

Different letters represent significant differences at P < 0.05 (Goodman test for contrast
between multinomial proportions)

Table 5. Distribution of P-glycoprotein staining percentage in relation to clinical
response to chemotherapy in animals with transmissible venereal tumor.
Positive

Negative

GROUP
n

%

n

%

Complete response
Partial response

6
13

31.57
68.43

13
10

56.52
43.48

Total

19

100

23

100

P = 0.19 by the chi-square test

staining (68.43%). Alternatively, the group with
complete response had a lower percentage of Pglycoprotein staining (31.57%). Despite the lack of a
significant difference, the biological effect was
apparent.
Discussion
The hypothesis that TVT presents different strains
of variable aggressiveness has already motivated the
use of this tripartite classification since 1994 by the
Veterinary Pathology Service of FMVZ, UNESP at
Botucatu, Sao Paulo, Brazil (7,26). The cells of the
lymphocytoid group are small, have a regular contour
with a round nucleus, and are generally concentric.
Those of the plasmocytoid group are voluminous, and
have an irregular contour with an eccentric nucleus
and abundant cytoplasm. By analyzing the frequency
of TVT cytomorphological types in the present study,
it can be observed that the plasmocytoid and mixed
classifications predominated in relation to the
lymphocytoid group.

The antibody anti-P-glycoprotein clone 5B12 did
not present positive staining in the tissues that
physiologically express P-glycoprotein. In the same
manner, it did not demonstrate antigen expression in
TVT cells. Although, as exemplified by other
antibodies such as clone C494, a cross-reaction exists,
in this case it was not observed. The use of different
monoclonal antibodies for the same molecule may be
recommended, given that not all epitopes of the
molecule have the same constitution of amino acids
(27). Probably, the amino-acid constitution of the
TVT cell epitope would not be compatible with the
clone 5B12, since it does not present immunostaining.
When the antibody anti-P-glycoprotein clone
C494 was utilized, satisfactory positive staining was
obtained with a 1:100 dilution of primary antibody,
both in positive controls and in TVT cells, as
recommended by Erünal-Maral et al. (14).
Considering that in oncology the increase in Pglycoprotein expression is related to an unfavorable
prognosis (22), the standardization of this antibody
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in cytological and histological preparations
constitutes an innovative parameter for definition of
prognosis in canine oncology and represents a
pioneering step in veterinary medicine.
Starting from the expression of P-glycoprotein
patterns, 4 categories were created. The first consists
of those tumors that always express P-glycoprotein.
The second comprise those that sometimes present Pglycoprotein expression. Tumors of the third category
rarely express P-glycoprotein. The fourth category
includes tumors that come to express P-glycoprotein
after chemotherapy. In the context of this
classification, it may be supposed that TVT would be,
imprecisely, within the first and second categories
(22).
The expression of P-glycoprotein by TVT suggests
that it can perform an important role in resistance to
chemotherapy against this neoplasia, similarly to that
cited by Miyoshi et al. (25), who, working with Pglycoprotein expression canines with mastocytoma,
observed that at least 26% of them expressed Pglycoprotein and, for this reason, could be resistant to
several different drugs.
The findings described above still corroborate the
results obtained by Moore et al. (19), Moral et al. (28),
and Lee et al. (29), in P-glycoprotein staining in
canine lymphoma; they observed that the most
malignant forms displayed strong P-glycoprotein
staining, which produced a direct relation between Pglycoprotein and multi-drug resistance in tumor cells.
In an analogous manner, human oncology studies on
the clinical importance of multi-drug resistance
(MDR) found that elevated levels of P-glycoprotein
expression correlate positively with lack of response
or remission after adequate forms of chemotherapy
(20).
Comparing the results of response to
chemotherapy among the 3 morphological groups, it
can be noted that the plasmocytoid group was
significantly less sensitive to chemotherapy in relation
to the lymphocytoid and mixed groups. When this
response was compared with P-glycoprotein
expression, a direct relation was observed between
partial response to chemotherapy and strong
expression of P-glycoprotein in the plasmocytoid
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group. Based on this result, it can be inferred that
clinical plasmocytoid TVT cases tend to present
partial clinical response to chemotherapy, possibly by
means of strong P-glycoprotein expression. In the
same manner, it can be established that by the results
obtained the lymphocytoid tumors responded
completely to chemotherapy, probably through low
expression of P-glycoprotein. This result agrees with
that of Bassani-Silva et al. (10), who found augmented
resistance to antitumoral action of propolis among
plasmocytoid cases.
When cytological preparations were regrouped
into primary and non-primary masses, it was
observed that P-glycoprotein presented higher
immunoreactivity in non-primary masses compared
with the primary mass group. Even though the
difference is not statistically significant, this result
suggests that the non-primary neoplasias can present
a potential to express resistance to chemotherapy. This
fact was also observed by Lee et al. (29) and by
Bergman et al. (30), who verified higher levels of Pglycoprotein expression in canine lymphomas in
relapse than in their initial expression. Thus,
according to Lee et al. (29), the P-glycoprotein
expression before the initiation of treatment is a
predictive factor independent of survival.
In conclusion, the expression of P-glycoprotein by
TVT may be involved in the resistance to
chemotherapy. Greater expression by plasmocytoid
tumors points to the greater malignancy of this
lineage. Determination of reactivity can constitute a
prognostic tool for this neoplasia.
The present results suggest the need for future
works that would identify oncogenes and antioncogenes expressed in the plasmocytoid and
lymphocytoid cytomorphological groups, in order to
evaluate whether the temporal sequence of mutations
in fact determines the malignancy of spontaneous
transmissible venereal tumors in dogs.
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